# Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

> **NCT07002398** · PHASE1,PHASE2 · RECRUITING · sponsor: **VeonGen Therapeutics GmbH** · enrollment: 15 (estimated)

## Conditions studied

- Retinal Dystrophy Due to Biallelic ABCA4 Mutations
- Stargardt Disease 1

## Interventions

- **DRUG:** VG801

## Key facts

- **NCT ID:** NCT07002398
- **Lead sponsor:** VeonGen Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07002398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07002398, "Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07002398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*